Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : InvestRight - Short Term Trading St -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (789)	1/26/1999 9:22:00 AM
From: CIN-CIU-E	Read Replies (1) \| Respond to of 939

-- American Biomed Receives European Patent for Its Bifurcated Stent Technology -- /FROM PR NEWSWIRE LOS ANGELES 213-626-5500/ TO BUSINESS, MEDICAL AND SCIENCE EDITORS: American Biomed Receives European Patent for Its Bifurcated Stent Technology - For Proprietary Dual Coil, Self-Expanding, Y-Shaped Stent for the Treatment of CardioVascular Disease Targeting an Estimated $2 Billion Market - THE WOODLANDS, Texas, Jan. 26 /PRNewswire/ -- American BioMed, Inc. (OTC Bulletin Board: ABMI), a leading medical device developer and manufacturer of minimally invasive devices for the treatment of cardiovascular disease and proprietary balloon catheters for cardiovascular, urinary and other disorders, today announced the European Patent Office ("EPO") granted the Company Patent No. 06471478 on December 16, 1998 entitled Method and Apparatus for Making a Stent. This patent, when coupled with the company's three U. S. patents covering its stent technology, further enhances the Company's proprietary technologies in this area. The EPO patent covers the Company's dual coil, self-expanding, nitinol bifurcated stent that supports a Y-shaped, juncture of two blood vessels. The Company will be registering the EPO patent in selected European countries during the First Quarter, 1999. Steven B. Rash, President and CEO of American BioMed, stated, "As the Company aggressively continues to protect its extensive patent position, we also are in active discussions with potential strategic partners to accelerate the commercialization of our proprietary stent technologies and to participate in the expanding $2 billion worldwide stent market." American BioMed, Inc. utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The Company's products include 100% silicone catheters, through its Cathlab subsidiary; the Evert-o-Cath(TM), a toposcopic catheter for site-specific drug delivery and fluid removal, the OmniCath(R), an atherectomy catheter designed to remove atherosclerotic plaque from obstructed blood vessels throughout the body; and the OmniFilter, which is used to prevent blood clots from reaching various organs of the body. The Company has over twenty-five patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be in excess of $10 billion. "Safe harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in the release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of pre-clinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive product development, commercialization and technological difficulties, the results of financing efforts, the effect of the Company's accounting policies, and other risks detailed in the Company's Securities and Exchange Commission filings. SOURCE American BioMed, Inc. /CONTACT: Steven B. Rash, President & CEO of American BioMed, Inc.,281-367-3895; or Stuart Bochler of International Market Advisors,732-591-0520, for American BioMed, Inc./ /Web site: americanbiomed.com Symbols: US;ABMI Source PRN - PR NewsWire Categories: NWR/TX NWI/MTC NWI/HEA

To: Jeffrey L. Henken who wrote (789)	1/26/1999 10:42:00 AM
From: Frank Buck	Read Replies (1) \| Respond to of 939

Jeff, The RDIM psychographic marketing approach certainly seems focussed and comprehensive. It is really amazing that none have attempted to build this type of customer interest base before. Sorry to hit you with so many questions but you are certainly an excellent source of information on many RDIM areas. So here comes a few more.... were there any discussion of: * Definitive RDIM Membership fees * How are they planning on getting the web type boxes into the hands of potential customers? At what cost and who will carry that cost? * Building and progress of the EDI (Electronic Data Interphase) infrastructure between vendors/mfgrs' and RDIM's physical locations as well as their portal site? * The amount of additional capital required to provide the overall unbuilt infrastructure and acquiring the physical catalog locations? * The time frame for the actual debut of the operational cyber commerce system? Ie. second or third quarter of '99. * What type of strains will RDIM's presence produce between Mfgrs'. and their traditional distribution channels... ie. retail? Thanks in advance for any input into these areas.